Skip to content

Journal · Geriatric pharmacology · Updated 21 November 2026

Drugs & Aging

Read Drugs & Aging articles on DeepDyve. No university library needed.

Drugs & Aging has published since 1991 and covers medicines and drug treatment in older adults, from polypharmacy and prescribing safety to frailty, vaccination and the care of chronic disease. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Drugs & Aging
Journal cover

Drugs & Aging at a glance

Full title
Drugs & Aging
Abbreviation (NLM)
Drugs Aging
Publisher
Springer Nature
Print ISSN
1170-229X
Online ISSN (eISSN)
1179-1969
First published
1991
Subjects
Drug Therapy, Geriatrics
Access model
Hybrid (49% free to read in 2026)

Ways to access Drugs & Aging

49% of the articles Drugs & Aging published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 49% of Drugs & Aging articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Drugs & Aging. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Drugs & Aging articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Drugs & Aging’s 2025 Journal Impact Factor is 4.2, and its 5-year Impact Factor is 4.0.

4.2

Journal Impact Factor (2025)

4.0

5-year Impact Factor (2025)

12 days

Median time to first decision

Source: journal metrics on the Drugs & Aging homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Drugs & Aging research worth reading

Published January to May 2026. Summaries describe what the authors report.

  1. LitStreamEpilepsy · Antiseizure medications

    Antiseizure Medications in Older Adults with Epilepsy: Considerations in Pharmacology, Safety, Tolerability, and Effectiveness of Newer Agents

    In a narrative review of antiseizure medication tolerability in adults aged 65 years and older, McCarthy and colleagues report that emerging evidence suggests newer agents show favorable efficacy and tolerability at lower doses, though falls, dizziness and neuropsychiatric effects can be dose limiting.

    McCarthy et al. · Drugs & Aging, published online February 18, 2026 · DOI 10.1007/s40266-026-01283-z

  2. Open accessMedication safety · Hospital discharge

    Bridging the Gap: Systematic Review of Strategies to Facilitate Post-Discharge Continuity of In-Hospital Medication Changes in Older Adults

    Reviewing 49 studies, Johnstone and colleagues report that most strategies for carrying hospital medication changes over after discharge in older adults were multi-component, and that 26 of the 36 studies assessing continuity found significant improvements, while clinical gains were rare.

    Johnstone et al. · Drugs & Aging, published online February 17, 2026 · DOI 10.1007/s40266-025-01270-w

  3. LitStreamPolypharmacy · Prescribing trends

    Australian Polypharmacy Trends Between 2013 and 2024: A Repeated Cross-Sectional Study in the Adult Population

    In a repeated cross-sectional study of Australian dispensing records, Lee and colleagues report that polypharmacy prevalence rose from 8.0% in 2013 to 9.2% over the study period, and that by 2024 men had surpassed women from middle age onward.

    Lee et al. · Drugs & Aging, published online January 11, 2026 · DOI 10.1007/s40266-025-01274-6

  4. LitStreamHeart failure · Older adults

    Guideline-Directed Heart Failure Pharmacotherapy in Adults Aged ≥75 Years: Evidence Gaps, Tolerability, and Implications for Clinical Practice

    In a structured narrative critical review of pivotal heart failure trials, Esser and colleagues report that mean participant age ranged from 61 to 67 years, with very limited inclusion of patients aged ≥75 years, and that frailty and other geriatric domains were rarely measured.

    Esser et al. · Drugs & Aging, published online May 22, 2026 · DOI 10.1007/s40266-026-01302-z

  5. LitStreamMenopause · Breast cancer survivorship

    Treating Genitourinary Syndrome of Menopause in Postmenopausal Women with a History of Breast Cancer

    Ferguson and colleagues review genitourinary syndrome of menopause, which affects up to 60% of breast cancer survivors, and describe a stepwise, symptom-driven treatment model that begins with non-hormonal options and advances to local vaginal therapies or ospemifene when appropriate.

    Ferguson et al. · Drugs & Aging, published online February 27, 2026 · DOI 10.1007/s40266-026-01287-9

See every Drugs & Aging article on DeepDyve

Questions about Drugs & Aging

How can I read Drugs & Aging articles without a subscription?

49% of Drugs & Aging articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Drugs & Aging articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Drugs & Aging?

Drugs & Aging’s NLM (PubMed) abbreviation is Drugs Aging.

What is the ISSN of Drugs & Aging?

The print ISSN is 1170-229X and the online ISSN is 1179-1969.

What is the impact factor of Drugs & Aging?

Drugs & Aging’s Journal Impact Factor is 4.2 (2025), and its 5-year Impact Factor is 4.0, according to Springer Nature’s published metrics.

Is Drugs & Aging open access?

Drugs & Aging is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 35 of 71 Drugs & Aging articles (49%) carry a Creative Commons license, per Crossref.

Drugs & Aging articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Drugs & Aging today

One month free, then less than $2 a day. Drugs & Aging, plus millions of articles from thousands of journals.

Start free month

Like this: